Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; 5 of the 31 sources its claims cite were checked for support.
Abstract
Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5-30 days after a "challenge" dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08-0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59-1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82-1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.
Overview
CoChat Summary
TL;DR
Systematic review and meta-analysis of poliovirus challenge studies found that OPV strongly reduces fecal poliovirus shedding after challenge, whereas IPV alone or added to OPV does not significantly reduce the prevalence of shedding. IPV may reduce the quantity and duration of virus shed, but evidence for nasopharyngeal mucosal protection was insufficient.
Key findings
- OPV-vaccinated individuals were protected against poliovirus shedding in stool after challenge compared with unvaccinated individuals: summary OR 0.13 (95% CI 0.08–0.24).
- IPV provided no significant protection against stool shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when added to OPV compared with OPV alone (summary OR 1.14 [95% CI 0.82–1.58]).
- Direct comparison of OPV versus IPV schedules favored OPV: overall OR 0.15 (95% CI 0.08–0.27).
- Five studies quantifying shedding found a 63%–91% (absolute 0.43–1.0 log10) reduction in mean quantity of poliovirus shed in stool among IPV-vaccinated compared with unvaccinated children; two of three studies examining duration found shorter shedding, and one study suggested combined quantity and duration reductions could reduce total virus shed by approximately 95%.
- There were insufficient studies of nasopharyngeal shedding to draw a conclusion.
Methods
- Systematic review of studies published through May 2011 identified via PubMed and Web of Knowledge, plus citation searching; 1,981 articles plus 6 additional studies were screened, yielding 31 stool-shedding studies and 4 nasopharyngeal-shedding studies meeting inclusion criteria.
- Inclusion required recording prevalence of vaccine poliovirus shedding in stool or nasopharyngeal samples collected 5–30 days after a challenge dose of live-attenuated poliovirus; exclusions included duplicate findings, immunocompromised individuals, fewer than 30 individuals, insufficient serotype/schedule/shedding data, or challenge more than 5 years after vaccination.
- Meta-analysis compared odds of shedding across vaccination categories—unvaccinated, trivalent OPV only, IPV only, and combined schedules—using fixed- or random-effects models according to heterogeneity, implemented in R with the rmeta package.
Limitations
- The paper states there were insufficient nasopharyngeal shedding studies to draw conclusions, and that few samples were positive with insufficient power to compare vaccination histories.
- The paper reports significant heterogeneity in some meta-analyses from variable sample timing, number/timing of vaccine doses, laboratory procedures, and unmeasured factors such as enteric infections; there were insufficient studies for a formal meta-regression.
- The paper states there are no studies with adequate control populations investigating IPV impact on wild-type poliovirus transmission in areas with efficient fecal-oral transmission, and that challenge with high-titer Sabin poliovirus differs from natural wild-type exposure; the relationship between quantity shed and onward transmission is unknown.
- Evident from the text: only 18 studies were included in the meta-analyses comparing vaccination histories, and only one study compared serotype 2 shedding in OPV-only versus OPV/IPV individuals, so no summary OR was calculated for that comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Flow diagram showing included studies according to PRISMA guidelines [46]. The number of published articles identified by the given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.](https://figures.cochat.ai/paper-figures/f7fa06a7c24446bdb28e75ad429edb87/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-1.jpg)
![Figure 2 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with unvaccinated individuals. Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The χ2 test for heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, <0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/cdf5934daf6143bea94adeadb60a35a7/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-2.jpg)
![Figure 3 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with unvaccinated individuals. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11, 0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/02e3301e07954edd96d8e51b7d7826c2/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-3.jpg)
![Figure 4 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values<0.001, 0.79, and 0.01 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/02290bcc61df4f4bbcf19524c4472bc4/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-4.jpg)
![Figure 5 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV compared with individuals vaccinated with OPV only. Labeling as for Figure 2. The schedule indicates the number and type of OPV doses received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 [49]). The χ2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).](https://figures.cochat.ai/paper-figures/f9e2423eecde4ebba5d508acc77f6bb4/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-5.jpg)
Verification
Claims the paper makes
4 Valid · 1 Not valid · 19 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response [7].”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Disputedcites [7] TM Herremans, 1999, Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus., J Immunol sourceExperimental — accuracy not yet measured
The Discussion says salivary IgG in IPV recipients was low or absent, suggesting it does not protect against mucosal poliovirus infection; any protective effect of circulating IgG remains untested. It instead attributes previously reported mucosal responses after IPV to prior priming with live virus and reports mucosal IgA responses after IPV boosting in previously OPV-vaccinated people. The proposed IgG-over-IgA explanation runs contrary to that account. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent evidence from India for waning intestinal immunity to poliovirus within a year of vaccination with OPV [38] and identification of wild-type polioviruses in stool samples from OPV immunized children [39] has generated interest in the potential for IPV to boost intestinal immunity among these children.”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Supportedcites [39] NC Grassly, 2010, Asymptomatic wild poliovirus infection in India among children previously immunized with oral poliovirus vaccine., J Infect Dis source
The Discussion reports that serotype 1 wild-type poliovirus was isolated from stool samples of children who reported receiving at least 10 OPV doses. This directly supports the identification attributed to this paper. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Five studies that quantified poliovirus shedding found a 63%–91% (or an absolute 0.43–1.0 log10) reduction in the mean quantity of poliovirus shed in stool samples collected from IPV vaccinated compared with unvaccinated children [5], [17]–[20] (Table S1).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Supportedcites [5] JL Henry, 1966, A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine., J Hyg (Lond) source
The ‘Amount of virus excreted after challenge’ section calculates mean virus content in feces and reports lower excretion in the killed-poliovaccine group than in the unvaccinated comparison group. This supports citing the paper as one of the five studies; the 63%–91% range describes the five studies collectively, not a result attributed to this paper alone. (LLM, conf=0.85)
- Not matchedcites [17]–[20]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The superior impact of OPV on intestinal mucosal immunity is confirmed by the meta-analysis of studies that directly compared schedules that exclusively used OPV or IPV (overall OR for OPV compared with IPV immunized children was 0.15 [0.08–0.27]).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, the prevalence of challenge poliovirus shedding was highly variable among studies, even for those that examined very similar vaccination schedules (Table S1).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 49 claims and to verify the 3 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IPV does not induce sufficient intestinal immunity to be effective in the prevention of virus spread [63,67].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“OPV vaccination is effective in preventing the shedding of WPV in the stool after exposure, which suggests that OPV induces sufficient intestinal mucosal immunity against PV infection and helps in the prevention of virus transmission [63].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [63]
Experimental — accuracy not yet measured
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Flow diagram showing included studies according to PRISMA guidelines”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Summary ORs and 95% confidence intervals were calculated on a log scale assuming either fixed effects or normally distributed random effects among studies according to the results of the x(2) test [44].”
MethodWang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Ogra, P. L., Karzon, D. T., Righthand, F., & MacGillivray, M. (1968) · New England Journal of Medicine · doi:10.1056/nejm196810242791701 · Cited by 397 · cited 2×
“In contrast, intramuscular injection of IPV induces serum antibodies but does not induce secretory IgA at the mucosal surfaces [3] and has a much more limited impact on the resistance of the intestine to infection [5].”
BackgroundBONE MARROW TRANSPLANTATION IN FIVE CHILDREN WITH SICKLE CELL ANAEMIA
Vermylen, C., Ninane, J., Fernandez Robles, E., & Cornu, G. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92239-8 · Cited by 196
Hovi, T., Huovilainen, A., Kuronen, T., Pöyry, T., Salama, N., Cantell, K., Kinnunen, E., Lapinleimu, K., Roivainen, M., Stenvik, M., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91566-7 · Cited by 186 · cited 1×
“Where importations of wild-type polioviruses to these countries have been documented, they have resulted in outbreaks ranging from a single case to over 100 cases of poliomyelitis [29–32].”
Background
Research works printed but not linked: 1
- G Enders-Ruckle, 1961, [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]., Dtsch Med Wochenschr, 86, 1999
Cited by
Human gut-associated lymphoid tissues (GALT); diversity, structure, and function
Mörbe, U. M., Jørgensen, P. B., Fenton, T. M., von Burg, N., Riis, L. B., Spencer, J., & Agace, W. W. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00389-4 · Cited by 424
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Insidious reintroduction of wild poliovirus into Israel, 2013
Anis, E., Kopel, E., Singer, S. R., Kaliner, E., Moerman, L., Moran-Gilad, J., Sofer, D., Manor, Y., Shulman, L. M., Mendelson, E., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.38.20586 · Cited by 162
“Ongoing national supplementary immunisation activity A supplementary immunisation activity using bivalent OPV [14,15] was initiated in the Southern district on 5 August 2013 and has been expanded nationally since 18 August, with the objective of rapidly interrupting WPV1 transmission across the country, particularly i…”
MethodKwon, K.-C., Verma, D., Singh, N. D., Herzog, R., & Daniell, H. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.005 · Cited by 150
Klapsa, D., Wilton, T., Zealand, A. M., Bujáki, E., Saxentoff, E. V., Troman, C. M., Shaw, A., Tedcastle, A. B., Majumdar, M., Mate, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01804-9 · Cited by 150
Self-citationVan Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31279-6 · Cited by 141
Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque
Edens, C., Dybdahl-Sissoko, N., Weldon, W. C., Oberste, M. S., & Prausnitz, M. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.01.089 · Cited by 126
Efficacy of inactivated poliovirus vaccine in India
Jafari, H., Deshpande, J. M., Sutter, R. W., Bahl, S., Verma, H., Ahmad, M., Kunwar, A., Vishwakarma, R., Agarwal, A., Jain, S., et al. (2014) · Science · doi:10.1126/science.1255006 · Cited by 112
Self-citationJohn, J., Giri, S., Karthikeyan, A. S., Iturriza-Gomara, M., Muliyil, J., Abraham, A., Grassly, N. C., & Kang, G. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60934-x · Cited by 109
Self-citationReinfection With SARS-CoV-2: Implications for Vaccines
Cohen, J. I., & Burbelo, P. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1866 · Cited by 112
“For example, the live attenuated oral poliovirus vaccine induces high levels of neutralizing antibody in the intestine to prevent infection and shedding of wild-type virus, while the inactivated poliovirus vaccine given intramus-cularly protects against disease, but not infection or shedding [36].”
BackgroundPoliovirus Vaccine–Inactivated
Vidor, E. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00047-x · Cited by 93
Troy, S. B., Kouiavskaia, D. V., Siik, J., Kochba, E., Beydoun, H. A., Mirochnitchenko, O. V., Levin, Y., Khardori, N. M., Chumakov, K., & Maldonado, Y. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu841 · Cited by 89
“Because IPV as a primary regimen is known to induce less intestinal immunity than OPV [32], and because reducing fecal transmission is essential to stopping community circulation of poliovirus, choosing an IPV vaccination strategy that results in high antibody titers would be beneficial.”
Matsuda, K., Migueles, S. A., Huang, J., Bolkhovitinov, L., Stuccio, S., Griesman, T., Pullano, A. A., Kang, B. H., Ishida, E., Zimmerman, M. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140794 · Cited by 88
Estimation of polio infection prevalence from environmental surveillance data
Berchenko, Y., Manor, Y., Freedman, L. S., Kaliner, E., Grotto, I., Mendelson, E., & Huppert, A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6786 · Cited by 82
“ES is especially useful in communities with high inactivated polio vaccine coverage, which confers good protection against paralysis but has limited effect against transmission (9, 10).”
BackgroundInfluentialLockhart, A. A. K., Mucida, D., & Parsa, R. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.007 · Cited by 91
Polio endgame: the global switch from tOPV to bOPV
Garon, J. R., Seib, K. G., Orenstein, W. A., Gonzalez, A. R., Blanc, D. C., Zaffran, M., & Patel, M. M. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1140041 · Cited by 85
The final stages of the global eradication of poliomyelitis
Grassly, N. C. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0140 · Cited by 80
Self-citationDaniell, H., Rai, V., & Xiao, Y. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.13060 · Cited by 74
“When compared to OPV, IPV does not induce adequate gastrointestinal mucosal immunity (Chan et al., 2016; Hird and Grassly, 2012).”
BackgroundGrassly, N. C. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit601 · Cited by 72
“Mucosal immunity induced by IPV against poliovirus shedding in stool is significantly reduced compared with OPV [35].”
ResultSelf-citationPoliovirus vaccine—inactivated
Vidor, E. J., & Plotkin, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00034-3 · Cited by 80
Parker, E. P. K., Molodecky, N. A., Pons-Salort, M., O’Reilly, K. M., & Grassly, N. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1052800 · Cited by 75
“In a recent meta-analysis, Hird and Grassly found no significant difference in the odds of viral shedding following OPV challenge among IPV-immunized compared with unvaccinated individuals [26].”
BackgroundSelf-citationPolio endgame: the global introduction of inactivated polio vaccine
Patel, M. M., Zipursky, S., Orenstein, W., Garon, J. R., & Zaffran, M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1001750 · Cited by 77
“However, IPV has been shown to reduce the duration of shedding and the amount of virus in the stool, as well as excretion of virus in those previously immunized with OPV [8,10,40].”
BackgroundSARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
Connors, M., Graham, B. S., Lane, H. C., & Fauci, A. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0111 · Cited by 75
Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines
Gupta, S., & Pellett, S. (2023) · Toxins · doi:10.3390/toxins15090563 · Cited by 92
“Some examples of killed vaccines include the polio vaccine [27] (inactivated poliovirus vaccine, IPV) and the rabies vaccine (inactivated rabies virus vaccine) [27,28].”
Pathophysiology of environmental enteric dysfunction and its impact on oral vaccine efficacy
Marie, C. S., Ali, A., Chandwe, K., Petri, W. A., & Kelly, P. M. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0036-1 · Cited by 76
Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US
Kiang, M. V., Bubar, K. M., Maldonado, Y., Hotez, P. J., & Lo, N. C. (2025) · JAMA · doi:10.1001/jama.2025.6495 · Cited by 83
Mucosal immunity to poliovirus
Connor, R. I., Brickley, E. B., Wieland‐Alter, W., Ackerman, M. E., Weiner, J. A., Modlin, J. F., Bandyopadhyay, A. S., & Wright, P. F. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00428-0 · Cited by 72
Guo, J., Bolivar-Wagers, S., Srinivas, N., Holubar, M. K., & Maldonado, Y. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.01.018 · Cited by 71
“outbreaks worldwide are caused by serotype 2 [9,64,65], and uncertainty remains regarding IPVs ability to provide enough mucosal protection against serotype 2 to prevent outbreaks caused by re-introduction of VDPV-2 in the post-tOPV era [66].”
BackgroundWright, P. F., Connor, R. I., Wieland‐Alter, W., Hoen, A. G., Boesch, A. W., Ackerman, M. E., Oberste, M. S., Gast, C., Brickley, E. B., Asturias, E. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30169-4 · Cited by 63
Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine
Zhao, T., Li, J., Fu, Y., Ye, H., Liu, X., Li, G., Yang, X., & Yang, J. (2020) · npj Vaccines · doi:10.1038/s41541-020-0194-5 · Cited by 63
Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
Thompson, K. M., & Kalkowska, D. A. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1791093 · Cited by 68
“from OPV and/or IPV against shedding, which concluded that immunization with IPV would likely show limited impact on poliovirus transmission in countries characterized by fecal-oral poliovirus transmission [94].”
BackgroundMethodDevelopment and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan
Shimizu, H. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.015 · Cited by 57
Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
Pons-Salort, M., Burns, C. C., Lyons, H. M., Blake, I. M., Jafari, H. S., Oberste, M. S., Kew, O. M., & Grassly, N. C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005728 · Cited by 60
“However, it is unclear what impact this vaccine will have on poliovirus transmission, which may well be limited as a result of the poor mucosal protection induced by this vaccine [36].”
BackgroundSelf-citationIntestinal Immunity Is a Determinant of Clearance of Poliovirus After Oral Vaccination
Wright, P. F., Wieland‐Alter, W., Ilyushina, N. A., Hoen, A. G., Arita, M., Boesch, A. W., Ackerman, M. E., van der Avoort, H., Oberste, M. S., Pallansch, M. A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit671 · Cited by 57
When Therapeutic IgA Antibodies Might Come of Age
Sterlin, D., & Gorochov, G. (2020) · Pharmacology · doi:10.1159/000510251 · Cited by 57
He, W., Baysal, C., Lobato-Gómez, M., Huang, X., Alvarez, D., Zhu, C., Armario-Nájera, V., Perera, A. B., Cerda‐Bennasser, P., Saba‐Mayoral, A., et al. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13658 · Cited by 55
“Although a mucosal vaccine against poliovirus is highly desirable, the Sabin Vaccine Institute’s live-attenuated vaccine (OPV2) was withdrawn by the WHO due to circulating vaccinederived polioviruses and polio virus transmission (Hird and Grassly, 2012; Minor, 2009; Yarri et al., 2013).”
BackgroundWhite, J. A., Blum, J. S., Hosken, N. A., Marshak, J. O., Duncan, L., Zhu, C., Norton, E. B., Clements, J. D., Koelle, D. M., Chen, D., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.32253 · Cited by 51
“In addition, fecal IgA may be important in prevention of viral shedding.(54) In our studies, the combination of serum and mucosal IgA responses were observed only in animals immunized by the SL route using the TRG delivery system—not in those immunized by the IM route, nor in those immunized by the SL route with only…”
BackgroundDuintjer Tebbens, R. J., & Thompson, K. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit838 · Cited by 48
The Israeli public health response to wild poliovirus importation
Kaliner, E., Kopel, E., Anis, E., Mendelson, E., Moran‐Gilad, J., Shulman, L. M., Singer, S. R., Manor, Y., Somekh, E., Rishpon, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00064-x · Cited by 51
Tebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1536-9 · Cited by 47
“Given that after the switch RI doses of IPV, which provides only limited intestinal immunity, [10–12] will represent the only poliovirus vaccine available for RI for”
BackgroundTebbens, R. J. D., Zimmermann, M. R., Pallansch, M. A., & Thompson, K. M. (2017) · Food and Environmental Virology · doi:10.1007/s12560-017-9314-4 · Cited by 52
“In addition, individuals immune to polio paralysis due to prior vaccination or poliovirus infection can still become infected and potentially participate in poliovirus transmission, particularly those vaccinated only with inactivated poliovirus vaccine (IPV) (Hird and Grassly 2012; Duintjer Tebbens et al. 2013).”
BackgroundInfluentialThe case for replacing live oral polio vaccine with inactivated vaccine in the Americas
Alfaro-Murillo, J. A., Avila-Aguero, M. L., Fitzpatrick, M. C., Crystal, C., Falleiros-Arlant, L. H., & Galvani, A. P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30213-0 · Cited by 47
Sáez‐Llorens, X., Clemens, R. L., Leroux-Roels, G. G., Jimeno, J., Clemens, S. A. C., Weldon, W. C., Oberste, M. S., Molina, N., & Bandyopadhyay, A. S. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00488-0 · Cited by 45
Brickley, E. B., Strauch, C. B., Wieland‐Alter, W., Connor, R. I., Lin, S., Weiner, J. A., Ackerman, M. E., Arita, M., Oberste, M. S., Weldon, W. C., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix556 · Cited by 41
“Several studies of poliovirus-specific immunoglobulin (Ig) A have provided evidence that prior exposure to live poliovirus, via OPV or environmental exposure, appears to be important for inducing mucosal responses to IPV immunization [12, 13], and a 2012 systematic review has demonstrated that, when delivered in the a…”
BackgroundMacklin, G., Grassly, N. C., Sutter, R. W., Mach, O., Bandyopadhyay, A. S., Edmunds, W. J., & O’Reilly, K. M. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30301-9 · Cited by 49
Self-citationInducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
Dietrich, J., Andreasen, L. V., Andersen, P. L., & Agger, E. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100879 · Cited by 40
“It is accepted that the major port of entry for the polio virus is the intestinal tract, and that fecal IgA is important in preventing entry of the pathogen [42,59].”
BackgroundImpact of COVID‐19 on polio vaccination in Pakistan: a concise overview
Din, M., Ali, H., Khan, M., Waris, A., Ullah, S., Kashif, M. A., Rahman, S., & Ali, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2190 · Cited by 43
“outbreak since it produces a relatively strong inhibitory humoral response which is important for preventing transmission.(20,21) Since the initial doses of inactivated polio vaccine (IPV) were enough for protection of the individuals against polio‐associated diseases, agreeing to receive OPV for prevention of transmi…”
BackgroundSynthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside
Ding, S., Alexander, E., Liang, H., Kulchar, R. J., SINGH, R. K., Herzog, R. W., Daniell, H., & Leong, K. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00482 · Cited by 51
Assessing the stability of polio eradication after the withdrawal of oral polio vaccine
Famulare, M., Selinger, C., McCarthy, K. A., Eckhoff, P. A., & Chabot‐Couture, G. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002468 · Cited by 41
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
Ciapponi, A., Bardach, A., Ares, L. R., Glujovsky, D., Cafferata, M. L., Cesaroni, S., & Aikant, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011260.pub2 · Cited by 45
Tebbens, R. J. D., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1114-6 · Cited by 36
“any secondary immunity to contacts [10, 17, 18].”
for the POG group, Yaari, R., Kaliner, E., Grotto, I., Katriel, G., Moran‐Gilad, J., Sofer, D., Mendelson, E., Miller, E., Huppert, A., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0637-z · Cited by 36
“OPV induces a strong gut immunity that limits transmission of the virus, whereas IPV induces humoral immunity that protects an individual from the risk of paralysis but has less impact on viral shedding and hence transmission [8].”
Shulman, L. M., Martín, J. E.-S., Sofer, D., Burns, C. C., Manor, Y., Hindiyeh, M. Y., Gavrilin, E., Wilton, T., Moran‐Gilad, J., Gamzo, R., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu1136 · Cited by 36
“High antibody titers protect against disease but do not induce “sterilizing immunity” (eg, prevent infection), but rather reduce thenumbers of excretors, the amounts excreted, and/or duration of excretion ([32–36] and references therein).”
BackgroundThe risk of type 2 oral polio vaccine use in post-cessation outbreak response
McCarthy, K. A., Chabot‐Couture, G., Famulare, M., Lyons, H. M., & Mercer, L. D. (2017) · BMC Medicine · doi:10.1186/s12916-017-0937-y · Cited by 33
“At the population scale, it is unclear how this reduction in acquisition at challenge doses translates to protection at natural exposure levels, and how the reduction in shedding translates to reduced infectiousness in close-contact and community settings in regions of poor sanitation [15, 27].”
BackgroundTebbens, R. J. D., Hampton, L. M., Wassilak, S. G. F., Pallansch, M. A., Cochi, S. L., & Thompson, K. M. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000340 · Cited by 32
“With the tOPV intensification that preceded the now completed switch, WPV1 confined to three countries, and IPV introduced in all countries that experienced WPV or cVDPV outbreaks since 2000, questions emerge regarding the need to continue to conduct frequent supplemental immunization activities (SIAs) with bOPV in po…”
BackgroundInfluentialThe Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
“The two types of vaccine used against the disease, injectable inactivated polio vaccine (IPV) and oral polio vaccine (OPV), have played a crucial role in reducing the number of cases [61,63].”
BackgroundImmune surveillance for vaccine-preventable diseases
den Hartog, G., van Binnendijk, R. S., Buisman, A., Berbers, G. A. M., & van der Klis, F. R. M. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1745071 · Cited by 33
“possibility of reverting to infectious virus [80,82].”
BackgroundKumar, P., Bird, C., Holland, D. A., Joshi, S. B., & Volkin, D. B. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2154100 · Cited by 36
Kawagishi, T., Sánchez-Tacuba, L., Feng, N., Costantini, V., Tan, M., Jiang, X., Green, K. Y., Vinjé, J., Ding, S., & Greenberg, H. B. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214421120 · Cited by 34
The Last Mile in Polio Eradication: Program Challenges and Perseverance
Cavestany, R. L., Eisenhawer, M., Diop, O. M., Verma, H., Quddus, A., & Mach, O. (2024) · Pathogens · doi:10.3390/pathogens13040323 · Cited by 31
“IPV and OPV induce a strong humoral response capable of protecting the vaccinated individual; however, only the latter has an established role in inducing mucosal intestinal immunity, which is essential to block viral transmission, making it a necessary tool for eradication [2].”
BackgroundThe Challenge of Global Poliomyelitis Eradication
Garon, J. R., Cochi, S. L., & Orenstein, W. A. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.07.003 · Cited by 33
“However, IPV is less effective in inducing intestinal mucosal immunity than OPV among previously unvaccinated individuals, although quantity and duration of sheddingmay be reduced.(13) For this reason, IPV does not provide the same amount of community protection against transmission that OPV does.”
Tebbens, R. J. D., & Thompson, K. M. (2016) · Epidemiology and Infection · doi:10.1017/s0950268816002302 · Cited by 29
Troy, S. B., Musingwini, G., Halpern, M. S., Huang, C., Stranix‐Chibanda, L., Kouiavskaia, D. V., Shetty, A. K., Chumakov, K., Nathoo, K., & Maldonado, Y. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit208 · Cited by 27
“As decreased poliovirus shedding is considered a marker for the development of mucosal intestinal immunity[25], this suggests that although uninfected children developed intestinal”
BackgroundBattistone, A., Buttinelli, G., Fiore, S., Amato, C., Bonomo, P., PATTI, A. M., Vulcano, A., Barbi, M., Binda, S., Pellegrinelli, L., et al. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.00108-14 · Cited by 30
“Because the IPV vaccine does not elicit a consistent mucosal immunity (10), silent transmission of neurovirulent poliovirus might in fact occur through IPV-immunized individuals, favoring possible infection of unvaccinated subjects or children receiving delayed IPV vaccination (11, 12).”
BackgroundTherapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Zhang, J., Zhang, H., & Sun, L. (2022) · mAbs · doi:10.1080/19420862.2022.2031483 · Cited by 29
“Another example is the oral poliovirus vaccine, which induces strong specific IgA responses to neutralize distinct serotypes.(141) Apart from an oral route, nasal administration is another strategy to induce sIgA in respiratory tracts.”
BackgroundProsocial polio vaccination in Israel
Wells, C. R., Huppert, A., Fitzpatrick, M. C., Pandey, A., Velan, B., Singer, B. H., Bauch, C. T., & Galvani, A. P. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922746117 · Cited by 24
“OPV elicits a relatively strong inhibitory humoral response that is essential for averting transmission and is advocated by the World Health Organization as the most effective approach for emergency outbreak control (11, 12).”
BackgroundEstívariz, C. F., Kovacs, S., & Mach, O. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.027 · Cited by 29
Use of inactivated poliovirus vaccine for poliovirus outbreak response
Bandyopadhyay, A. S., Cavestany, R. L., Blake, I. M., Macklin, G., Cooper, L., Grassly, N. C., Nery, A. L. M. D. S., & Mach, O. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00505-4 · Cited by 29
Self-citationOchoge, M., Futa, A. C., Umesi, A., Affleck, L., Kotei, L., Daffeh, B., Saidy-Jah, E., Njie, A., Oyadiran, O. T., Edem, B. E., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02844-1 · Cited by 27
Innate and adaptive immune responses that control lymph-borne viruses in the draining lymph node
Melo‐Silva, C. R., & Sigal, L. J. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01188-0 · Cited by 30
Thompson, K. M., & Tebbens, R. J. D. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1116-4 · Cited by 27
“For example, the kinetics of waning remain uncertain and intestinal immunity may wane more steeply after 5 or more years [32] than assumed in our model [17] based on the limited evidence [28, 31, 33], which would result in more cVDPV emergences and cases both before and after OPV2 cessation.”
BackgroundPublic health response to the silent reintroduction of wild poliovirus to Israel, 2013–2014
Moran‐Gilad, J., Kaliner, E., Gdalevich, M., & Grotto, I. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.06.018 · Cited by 23
“The Israeli experience suggests that poliovirus can silently circulate in countries using IPV exclusively (and presumably lacking mucosal gut immunity in the population [19,20]) and that such circulation could be expected to go undetected using standard AFP surveillance.”
BackgroundMangal, T. D., Aylward, R. B., & Grassly, N. C. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt203 · Cited by 28
“of poliovirus shedding in stools following a dose of OPV is unaffected by IPV, but studies have shown that the amount of poliovirus shed is reduced by 63%–91% (10, 34–39) and that the duration of shedding is approximately halved following 2 doses of IPV (10, 35, 37).”
InfluentialSelf-citationBrickley, E. B., Wieland‐Alter, W., Connor, R. I., Ackerman, M. E., Boesch, A. W., Arita, M., Weldon, W. C., O’Ryan, M., Bandyopadhyay, A. S., & Wright, P. F. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy603 · Cited by 26
“Although the relative protection afforded by polio vaccines is most commonly inferred from changes in serum antibody levels, a growing number of studies, 18 of which were meta-analyzed by Hird and Grassly [10], have used an OPV challenge Figure 5.”
BackgroundTebbens, R. J. D., Pallansch, M. A., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130123 · Cited by 25
“[10, 23] Numerous prior studies demonstrated very limited intestinal immunity provided by IPV-only in fully susceptible individuals,[27, 39, 40] which implies a very limited impact of IPV alone on population immunity in settings conducive to fecal-oral poliovirus transmission.”
BackgroundPotential for use of retinoic acid as an oral vaccine adjuvant
Lisulo, M. M., & Kelly, P. M. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0145 · Cited by 25
Shirreff, G., Wadood, M. Z., Vaz, R. G., Sutter, R. W., & Grassly, N. C. (2016) · Emerging infectious diseases · doi:10.3201/eid2302.161210 · Cited by 26
“However, immunization with IPV alone induces very limited intestinal mucosal immunity against viral shedding compared with that induced by OPV, and therefore, IPV may be permissive to poliovirus circulation even when vaccination coverage is high (10,11).”
BackgroundSelf-citationPellegrinelli, L., Bubba, L., Prímache, V., Pariani, E., Battistone, A., Delogu, R., Fiore, S., & Binda, S. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1264726 · Cited by 23
Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine
Gamage, D. G., Mach, O., Palihawadana, P., Zhang, Y., Weldon, W. C., Oberste, M. S., Gunasena, S., & Sutter, R. W. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy389 · Cited by 25
“Given the length of time between the last dose of OPV (at school entry contact) and the age of the children, we assumed that their mucosal immunity had waned [8, 9, 23].”
Bashorun, A. O., Hydara, M. B., Adigweme, I., Umesi, A., Danso, B., Johnson, N., Sambou, N. A., Fofana, S., Kanu, F. J., Jeyaseelan, V., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00497-6 · Cited by 22
Chaturvedi, S., Beutler, N., Vasen, G., Pablo, M., Chen, X., Calia, G., Buie, L., Rodick, R., Smith, D. M., Rogers, T. F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204624119 · Cited by 24
Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA
Stolovich-Rain, M., Kumari, S., Friedman, A., Kirillov, S., Socol, Y., Billan, M., Pal, R. R., Das, K., Golding, P., Oiknine‐Djian, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933347 · Cited by 25
“The well-studied poliovirus case with the known difference between inactivated polio vaccine and oral polio vaccine exemplifies the importance of such mimicry for providing sterilizing immunity (77, 78).”
BackgroundKennedy, S. B., Macklin, G., Ross, G. M., Cavestany, R. L., Moukom, R. A., Jones, K. A. V., Mainou, B. A., Massaquoi, M. B. F., Kieh, M., & Mach, O. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00116-x · Cited by 23
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance
Sutter, R. W., Eisenhawer, M., Molodecky, N. A., Verma, H., & Okayasu, H. (2024) · Pathogens · doi:10.3390/pathogens13030224 · Cited by 30
“The available evidence on IPV mucosal immunity was reviewed [32–34].”
BackgroundLim, E. S., Cao, S., Holtz, L. R., et al. (2014) · Virology · doi:10.1016/j.virol.2014.01.018 · Cited by 22
“For example, poliovirus, a member of the Picornaviridae, causes neurological disease but has been well documented to be shed in stool (Hird and Grassly, 2012).”
BackgroundPons-Salort, M., Molodecky, N. A., O’Reilly, K. M., Wadood, M. Z., Safdar, R. M., Etsano, A., Vaz, R. G., Jafari, H. S., Grassly, N. C., & Blake, I. M. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002140 · Cited by 23
Self-citationPre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infectionPreprint
Moore, A., Dora, E. G., Peinovich, N., Tucker, K., Lin, K., Cortese, M., & Tucker, S. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.04.283853 · Cited by 22
Troy, S. B., Ferreyra-Reyes, L. D., Huang, C., Sarnquist, C., Canizales‐Quintero, S., Nelson, C. N., Báez-Saldaña, R., Holubar, M. K., Ferreira-Guerrero, E., García‐García, L., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit831 · Cited by 21
“Given that IPV is known to confer inferior intestinal immunity than OPV [24], it is possible that serotype 2 exhibits higher levels of community circulation in communities that are either undervaccinated or primarily vaccinated with IPV but not in communities primarily vaccinated with OPV.”
BackgroundMach, O., Verma, H., Khandait, D. W., Sutter, R. W., O’Connor, P. M., Pallansch, M. A., Cochi, S. L., Linkins, R. W., Chu, S. Y., Wolff, C., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit234 · Cited by 22
Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains
Puligedda, R. D., Kouiavskaia, D. V., Adekar, S. P., Sharma, R., Kattala, C. D., Rezapkin, G. V., Bidzhieva, B., Dessain, S. K., & Chumakov, K. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.05.005 · Cited by 23
Kidd, S., Clark, T. A., Routh, J. A., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7249a3 · Cited by 20
Crothers, J. W., Ross Colgate, E., Cowan, K. J., Dickson, D. M., Walsh, M., Carmolli, M., Wright, P. F., Norton, E. B., & Kirkpatrick, B. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.056 · Cited by 18
Tebbens, R. J. D., & Thompson, K. M. (2017) · MDM Policy & Practice · doi:10.1177/2381468317697002 · Cited by 20
A mucosal adjuvant for the inactivated poliovirus vaccine
Steil, B. P., Jorquera, P. A., Westdijk, J., Bakker, W. A. M., Johnston, R. E., & Barro, M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.101 · Cited by 19
A quantitative survey of the literature on poliovirus infection and immunity
Behrend, M. R., Hu, H., Nigmatulina, K. R., & Eckhoff, P. A. (2013) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.09.005 · Cited by 25
Bandyopadhyay, A. S., Gast, C., Brickley, E. B., Rüttimann, R. W., Clemens, R. L., Oberste, M. S., Weldon, W. C., Ackerman, M. E., Connor, R. I., Wieland‐Alter, W., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa390 · Cited by 19
“OPV replicates in the gut and induces primary intestinal immunity, an essential factor to control person-to-person transmission in settings of poor hygiene [7].”
BackgroundGlobal age-stratified seroprevalence of enterovirus D68: a systematic literature review
Jorgensen, D., Grassly, N. C., & Pons-Salort, M. (2024) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.07.001 · Cited by 23
Self-citationJohn, J. K., Giri, S., Karthikeyan, A. S., Lata, D., Jeyapaul, S., Kasirajan, A., Kumar, N., Dhanapal, P., Jayalakshmi, V., Mohanraj, M., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw595 · Cited by 24
Self-citationDeng, L., Roose, K., Job, E. R., Rycke, R. M. D., Hamme, E. V., Gonçalves, A. C., Parthoens, E., Cicchelero, L., Sanders, N. N., Fiers, W. C., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.020 · Cited by 21
Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Collett, M. S., Hartford, M., van der Avoort, H., Boesch, A. W., Weiner, J. A., Ackerman, M. E., McKinlay, M. A., et al. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2019-001613 · Cited by 18
Metadata
- Authors
- Hird, T. R., & Grassly, N. C.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Grassly, Nicholas C.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e1002599
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3330118
- OpenAlex
- W1971110767
- Cited by
- 221
- References
- 55
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 22 · 2016: 18 · 2015: 20 · 2014: 21 · 2013: 11 · 2012: 2
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- inactivated poliovirus vaccine, oral polio vaccine, mucosal immunity, intestinal immunity, polio eradication, vaccine challenge, fecal-oral transmission, poliomyelitis control
- MeSH terms
- Animals, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Virus Shedding, Poliovirus, Immunity, Mucosal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.